Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	515.55	180.13	-	-	-	-
Cost of Revenue	19.18	6.23	-	-	-	-
Gross Profit	496.37	173.9	-	-	-	-
Selling, General & Admin	613.54	435.06	108.15	48.13	37.32	21.86
Research & Development	192.64	236.72	272.35	245.44	205.16	184.81
Operating Expenses	806.19	671.78	380.5	293.57	242.48	206.67
Operating Income	-309.81	-497.88	-380.5	-293.57	-242.48	-206.67
Interest Expense	-13.74	-14.67	-12.71	-3.96	-	-
Interest & Investment Income	41.7	46.65	19.58	2.19	0.36	4.33
Other Non Operating Income (Expenses)	-0.04	-	-	-	0.27	0.1
EBT Excluding Unusual Items	-281.9	-465.89	-373.63	-295.35	-241.85	-202.24
Pretax Income	-281.9	-465.89	-373.63	-295.35	-241.85	-202.24
Net Income	-281.9	-465.89	-373.63	-295.35	-241.85	-202.24
Net Income to Common	-281.9	-465.89	-373.63	-295.35	-241.85	-202.24
Shares Outstanding (Basic)	22	21	19	17	17	15
Shares Outstanding (Diluted)	22	21	19	17	17	15
Shares Change (YoY)	10.46%	13.83%	9.05%	3.64%	7.05%	0.34%
EPS (Basic)	-12.82	-21.90	-19.99	-17.23	-14.63	-13.09
EPS (Diluted)	-12.82	-21.90	-19.99	-17.23	-14.63	-13.09
Free Cash Flow	-308.39	-457.03	-325.71	-225.07	-184.13	-157.9
Free Cash Flow Per Share	-14.02	-21.48	-17.43	-13.13	-11.13	-10.22
Gross Margin	96.28%	96.54%	-	-	-	-
Operating Margin	-60.09%	-276.39%	-	-	-	-
Profit Margin	-54.68%	-258.64%	-	-	-	-
Free Cash Flow Margin	-59.82%	-253.72%	-	-	-	-
EBITDA	-308.4	-496.78	-379.97	-293.1	-242.08	-206.2
EBITDA Margin	-59.82%	-275.78%	-	-	-	-
D&A For EBITDA	1.42	1.1	0.53	0.47	0.41	0.47
EBIT	-309.81	-497.88	-380.5	-293.57	-242.48	-206.67
EBIT Margin	-60.09%	-276.39%	-	-	-	-

Updated Aug 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q